WASHINGTON UNIVERSITY SCHOOL OF MEDICINE

[212Pb]VMT-α-NET showed favorable safety and anti-tumor activity in a Phase 1/2a trial, with eight of nine patients experiencing durable disease control and six showing tumor volume reduction. Dose escalation is ongoing at 5.0 mCi.

Researchers at WashU Medicine engineered a yeast probiotic to deliver immunotherapy directly to the gut, shrinking gastrointestinal tumors in mice, offering a novel strategy for hard-to-reach gut cancers.

Eisai and Biogen received a positive CHMP opinion recommending approval of lecanemab, an Aß monoclonal antibody for early Alzheimer’s disease in ApoE e4 non-carriers or heterozygotes. Lecanemab selectively binds to Aß aggregates, reducing protofibrils and plaques. The CHMP's positive opinion was based on phase 3 Clarity AD trial data, showing significant reduction in clinical decline. Lecanemab has been approved in several countries and is under review in others.

WashU Medicine and BJC Health System launch Center for Health AI to leverage AI for personalized, efficient care, aiming to reduce clinician burnout and enhance patient experience. Led by Philip R.O. Payne and Deborah O'Dell, the center will focus on AI-driven solutions, training future health leaders, and fostering cross-organizational collaboration.

Eisai and Biogen announce CHMP positive opinion for lecanemab, an Aβ monoclonal antibody for early Alzheimer’s disease, with the European Commission expected to make a final decision within 67 days.

CHMP recommends EU approval of lecanemab for early Alzheimer’s in ApoE ε4 heterozygotes or non-carriers, following Eisai’s re-examination request. Decision expected within 67 days.

A clinical trial at WashU Medicine shows a neoantigen DNA vaccine is safe and elicits immune responses in triple-negative breast cancer patients, with 16 out of 18 remaining cancer-free after three years.

Proteogenomic analysis identifies neurologically relevant regulation and causal proteins for Alzheimer’s disease. Supported by NIH, Chan Zuckerberg Initiative, Michael J. Fox Foundation, and others. Cruchaga received research support from GSK and Eisai, and is on the advisory board of Circular Genomics.